KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Assets Average (2016 - 2025)

Emergent BioSolutions' Assets Average history spans 15 years, with the latest figure at $1.4 billion for Q4 2025.

  • For Q4 2025, Assets Average fell 3.07% year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $1.4 billion, down 3.07%, while the annual FY2025 figure was $1.4 billion, 15.71% down from the prior year.
  • Assets Average reached $1.4 billion in Q4 2025 per EBS's latest filing, down from $1.4 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $3.1 billion in Q1 2023 to a low of $1.4 billion in Q4 2025.
  • Average Assets Average over 5 years is $2.2 billion, with a median of $2.3 billion recorded in 2023.
  • Peak YoY movement for Assets Average: rose 25.56% in 2021, then crashed 40.7% in 2024.
  • A 5-year view of Assets Average shows it stood at $2.9 billion in 2021, then grew by 4.07% to $3.0 billion in 2022, then plummeted by 38.7% to $1.9 billion in 2023, then decreased by 22.84% to $1.4 billion in 2024, then fell by 3.07% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for EBS's Assets Average are $1.4 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.4 billion (Q2 2025).